-
1Academic Journal
Authors: Tatiana M. Reshetnyak, Fariza A. Cheldieva, Svetlana I. Glukhova, Kamila S. Nurbaeva, Nataliya V. Seredavkina, Mariya V. Cherkasova, Alexander M. Lila, Evgeny L. Nasonov, Т. М. Решетняк, Ф. А. Чельдиева, С. И. Глухова, К. С. Нурбаева, Н. В. Середавкина, М. В. Черкасова, А. М. Лила, Е. Л. Насонов
Contributors: Статья подготовлена в рамках темы ФГБНУ НИИР им. В.А. Насоновой FURS-2022-003 (№ 122040400024-7), и исследование одобрено локальным этическим комитетом.
Source: Rheumatology Science and Practice; Vol 62, No 4 (2024); 408–417 ; Научно-практическая ревматология; Vol 62, No 4 (2024); 408–417 ; 1995-4492 ; 1995-4484
Subject Terms: антитела к комплексу фосфатидилсерин/протромбин, antiphospholipid antibodies, recurrent thromboses, systemic lupus erythematosus, antibodies to cardiolipin, antibodies to ß2-glycoprotein 1, antibodies to phosphatidylserine/prothrombin complex, антифосфолипидные антитела, рецидивы тромбозов, системная красная волчанка, антитела к кардиолипину, антитела к бета-2-гликопротеину 1
File Description: application/pdf
Relation: https://rsp.mediar-press.net/rsp/article/view/3608/2390; Решетняк ТМ. Антифосфолипидный синдром: диагностика и клинические проявления (лекция). Научно-практическая ревматология. 2014;52(1):56-71. doi:10.14412/19954484-2014-56-71.; Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006;4(2):295-306. doi:10.1111/j.1538-7836.2006.01753.x; Насонов ЕЛ (ред.). Антифосфолипидный синдром. М.:Литте рра;2004. [Nasonov EL (ed.). Antiphospholipid syndrome. Moscow:Litterra;2004 (In Russ.)].; Решетняк ТМ, Чельдиева ФА, Нурбаева КС, Лила АМ, Насонов ЕЛ. Антифосфолипидный синдром: диагностика, механизм развития, вопросы терапии. Тромбоз, гемостаз и реология. 2020;4:4-21. doi:10.25555/THR.2020.4.0940.; Bazzan M, Vaccarino A, Stella S, Sciascia S, Montaruli B, Bertero MT, et al.; Piedmont APS Consortium. Patients with antiphosholipid syndrome and thrombotic recurrences: A real world observation (the Piedmont cohort study). Lupus. 2016;25(5):479-485. doi:10.1177/0961203315617538; Brey RL, Muscal E, Chapman J. Antiphospholipid antibodies and the brain: A consensus report. Lupus. 2011;20(2):153-157. doi:10.1177/0961203310396748; Knight JS, Branch DW, Ortel TL. Antiphospholipid syndrome: Advances in diagnosis, pathogenesis, and management. BMJ. 2023;380:e069717. doi:10.1136/bmj-2021-069717; Taraborelli M, Reggia R, Dall’Ara F, Fredi M, Andreoli L, Gerosa M, et al. Longterm outcome of patients with primary antiphospholipid syndrome: A retrospective multicenter study. J Rheumatol. 2017;44(8):1165-1172. doi:10.3899/jrheum.161364; Jackson WG, Oromendia C, Unlu O, Erkan D, DeSancho MT; Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking. Recurrent thrombosis in patients with antiphospholipid antibodies and arterial thrombosis on antithrombotic therapy. Blood Adv. 2017;1(25):2320-2324. doi:10.1182/bloodadvances.2017008185; Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML. GAPSS: The global anti-phospholipid syndrome score. Rheumatology (Oxford). 2013;52(8):1397-1403. doi:10.1093/rheumatology/kes388; Radin M, Schreiber K, Costanzo P, Cecchi I, Roccatello D, Baldovino S, et al. The adjusted Global AntiphosPholipid Syndrome Score (aGAPSS) for risk stratification in young APS patients with acute myocardial infarction. Int J Cardiol. 2017;240:72-77. doi:10.1016/j.ijcard.2017.02.155; Чельдиева ФА, Решетняк ТМ, Шумилова АА, Нурбаева КС, Черкасова МВ, Лила АМ, и др. Общий индекс антифосфолипидного синдрома (GAPSS) у пациентов с системной красной волчанкой. Научно-практическая ревматология. 2022; 60(5):546-553. doi:10.47360/1995-4484-2022-546-553; Abu-Zeinah G, Oromendia C, DeSancho MT. Thrombotic risk factors in patients with antiphospholipid syndrome: A single center experience. J Thromb Thrombolysis. 2019;48(2):233-239. doi:10.1007/s11239-019-01836-7; Galli M, Luciani D, Bertolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: A systematic review of the literature. Blood. 2003;101(5):1827-1832. doi:10.1182/blood-2002-02-0441; Andreoli L, Chighizola CB, Banzato A, Pons-Estel GJ, Ramire de Jesus G, Erkan D. Estimated frequency of antiphospholipid antibodies in patients with pregnancy morbidity, stroke, myocardial infarction, and deep vein thrombosis: A critical review of the literature. Arthritis Care Res (Hoboken). 2013;65(11):1869-1873. doi:10.1002/acr.22066; Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Schur PH, Hennekens CH, et al. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med. 1992;117(12):997-1002. doi:10.7326/0003-4819-117-12-997; Levine SR, Brey RL, Tilley BC, Thompson JL, Sacco RL, Sciacca RR, et al.; APASS Investigators. Antiphospholipid antibodies and subsequent thrombo-occlusive events in patients with ischemic stroke. JAMA. 2004;291(5):576-584. doi:10.1001/jama.291.5.576; Janardhan V, Wolf PA, Kase CS, Massaro JM, D’Agostino RB, Franzblau C, et al. Anticardiolipin antibodies and risk of ischemic stroke and transient ischemic attack: The Framingham cohort and offspring study. Stroke. 2004;35(3):736-741. doi:10.1161/01.STR.0000117575.48205.2D; Arvanitakis Z, Brey RL, Rand JH, Schneider JA, Capuano AW, Yu L, et al. Relation of antiphospholipid antibodies to postmortem brain infarcts in older people. Circulation. 2015;131(2):182-189. doi:10.1161/CIRCULATIONAHA.114.012479; Anand P, Mann SK, Fischbein NJ, Lansberg MG. Bilateral internal carotid artery occlusion associated with the antiphospholipid antibody syndrome. Case Rep Neurol. 2014;6(1):50-54. doi:10.1159/000360473; Etemadifar M, Dehghani L, Tahani S, Toghianifar N, Rahaimi M, Eskandari N. Neurological manifestations in patients with antiphospholipid syndrome. Iran J Neurol. 2013;12(4):172-175.; Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997;40(9):1725. doi:10.1002/art.1780400928; Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum. 2012;64(8):2677-2686. doi:10.1002/art.34473; Решетняк ТМ, Чельдиева ФА, Черкасова МВ, Лила АМ. Клиническое значение антител к комплексу фосфатидилсерин/протромбин. Современная ревматология. 2022;16(2):8186. doi:10.14412/1996-7012-2022-2-81-86; Barbhaiya M, Zuily S, Naden R, Hendry A, Manneville F, Amigo MC, et al.; ACR/EULAR APS Classification Criteria Collaborators. The 2023 ACR/EULAR antiphospholipid syndrome classification criteria. Arthritis Rheumatol. 2023;75(10):1687-1702. doi:10.1002/art.42624; Zhang S, Wu Z, Li P, Bai Y, Zhang F, et al. Evaluation of the clini cal performance of a novel chemiluminescent immunoassay for detection of anticardiolipin and anti-beta2-glycoprotein 1 antibodies in the diagnosis of antiphospholipid syndrome. Medicine (Baltimore). 2015;94(46):e2059. doi:10.1097/MD.0000000000002059; Ünlü O, Zuily S, Erkan D. The clinical significance of antiphospholipid antibodies in systemic lupus erythematosus. Eur J Rheumatol. 2016;3(2):75-84. doi:10.5152/eurjrheum.2015.0085; Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis. 2019;78(10):1296-1304. doi:10.1136/annrheumdis-2019-215213; Kearon C, Parpia S, Spencer FA, Baglin T, Stevens SM, Bauer KA, et al. Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism. Blood. 2018;131(19):2151-2160. doi:10.1182/blood-2017-09-805689; Pengo V, Ruffatti A, Legnani C, Gresele P, Barcellona D, Erba N, et al. Clinical course of high-risk patients diagnosed with antiphospholipid syndrome. J Thromb Haemost. 2010;8(2):237-242. doi:10.1111/j.1538-7836.2009.03674.x; Foddai SG, Radin M, Cecchi I, Rubini E, Barinotti A, Alba P, et al. 2023 ACR/EULAR classification criteria in existing research cohorts: An international study. Rheumatology (Oxford). 2024 Jan 30:keae 058. doi:10.1093/rheumatology/keae058; Cheldieva FA, Shumilova AA, Cherkasova MV, Glukhova SI, Lila AM, Nasonov EL, et al. Risk factors and recurrent thrombosis in primary antiphospholipid syndrome. Explor Immunol. 2023;3:475-489. doi:10.37349/ei.2023.00114; Dufrost V, Darnige L, Reshetnyak T, Vorobyeva M, Jiang X, Yan XX, et al. New insights into the use of direct oral anticoagulants in non-high risk thrombotic APS patients: Literature review and subgroup analysis from a meta-analysis. Curr Rheumatol Rep. 2020;22(7):25. doi:10.1007/s11926-020-00901-y; Correa RCR, Franco CJV, Muñoz-Grajales C, Peñaranda LFP, Hernández JD, Padilla LMR, et al. Use of factor Xa inhibitors in antiphospholipid antibodies syndrome: A series of seven cases. Revista Colombiana de Reumatología. 2018;25(1):16-21. doi:10.1016/j.rcreu.2017.07.004; Dufrost V, Risse J, Reshetnyak T, Satybaldyeva M, Du Y, Yan XX, et al. Increased risk of thrombosis in antiphospholipid syndrome patients treated with direct oral anticoagulants. Results from an international patient-level data meta-analysis. Autoimmun Rev. 2018;17(10):1011-1021. doi:10.1016/j.autrev.2018.04.009; Селиверстов ЕИ, Лобастов КВ, Илюхин ЕА, Апханова ТВ, Ахметзянов РВ, Ахтямов ИФ, и др. Профилактика, диагностика и лечение тромбоза глубоких вен. Рекомендации российских экспертов. Флебология. 2023;17(3):152-296. doi:10.17116/flebo202317031152; Navarro-Carpentieri D, Del Carmen Castillo-Hernandez M, Majluf-Cruz K, Espejo-Godinez G, Carmona-Olvera P, Moreno- Hernandez M, et al. Impact of classical risk factors for arterial or venous thrombosis in patients with antiphospholipid syndrome. Clin Appl Thromb Hemost. 2018;24(5):834-840. doi:10.1177/1076029617727859; Решетняк ТМ, Середавкина НВ, Мач ЭС, Александрова ЕН, Новиков АА, Черкасова МВ, и др. Cубклинические и клинические проявления атеросклероза при антифосфолипидном синдроме. Терапевтический архив. 2008;80(10):6067.; Berman H, Ugarte-Gil MF, Espinosa G, Tаssies D, Monteagudo J, Reverter JC, et al. Can inherited thrombophilia modulate the clinical phenotype of patients with antiphospholipid syndrome? Clin Exp Rheumatol. 2013;31(6):926-932.; Diz-Kucukkaya R, Hancer VS, Artim-Esen B, Pekcelen Y, Inanc M. The prevalence and clinical significance of inherited thrombophilic risk factors in patients with antiphospholipid syndrome. J Thromb Thrombolysis. 2010;29(3):303-309. doi:10.1007/s11239-009-0356-9; Решетняк ТМ, Патрушев ЛИ, Стукачева ЕА, Мирошников АИ, Тихонова ТЛ, Насонов ЕЛ, и др. Мутации Leiden, G 20210A в гене протромбина и антфосфолипидные антитела при системной красной волчанке и антифосфолипидном синдроме. Терапевтический архив. 2000;72(5):34-38.
-
2Academic Journal
Authors: T. M. Reshetnyak, F. A. Cheldieva, M. V. Cherkasova, A. M. Lila, Т. М. Решетняк, Ф. А. Чельдиева, М. В. Черкасова, А. М. Лила
Source: Modern Rheumatology Journal; Том 16, № 2 (2022); 81-86 ; Современная ревматология; Том 16, № 2 (2022); 81-86 ; 2310-158X ; 1996-7012
Subject Terms: антитела к комплексу фосфатидилсерин/протромбин, antiphospholipid syndrome, systemic lupus erythematosus, thrombosis, obstetric pathology, antibodies to prothrombin, antibodies to the phosphatidylserine/prothrombin complex, антифосфолипидный синдром, системная красная волчанка, тромбоз, акушерская патология, антитела к протромбину
File Description: application/pdf
Relation: https://mrj.ima-press.net/mrj/article/view/1279/1233; Ruiz-Irastorza G, Crowther M, Branch W, Khamashta MA. Antiphospholipid syndrome. Lancet. 2010 Oct 30;376(9751):1498-509. doi:10.1016/S0140-6736(10)60709-X; Решетняк ТМ, Чельдиева ФА, Нурбаева КС и др. Антифосфолипидный синдром: диагностика, механизм развития, вопросы терапии. Тромбоз, гемостаз и реология. 2020;(4):4-21.; Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med. 2013 Mar 14;368(11):1033-44. doi:10.1056/NEJMra1112830.; Насонов ЕЛ. Антифосфолипидный синдром. Монография. Москва: Литтера; 2004. С. 36.; Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006 Feb;4(2):295-306. doi:10.1111/j.1538-7836.2006.01753.x.; Bertolaccini ML. Antibodies to prothrombin. Lupus. 2012 Jun;21(7):729-31. doi:10.1177/0961203312443299.; Чельдиева ФА, Решетняк ТМ, Лила АМ. Антифосфолипидные антитела и их клиническое значение. Тромбоз, гемостаз и реология. 2021;(2):4-15.; Bertolaccini ML, Gomez S, Pareja JF, et al. Antiphospholipid antibody tests: spreading the net. Ann Rheum Dis. 2005 Nov;64(11):1639-43. doi:10.1136/ard.2005.035824.; Bertolaccini ML, Amengual O, Atsumi T, et al. 'Non-criteria' aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010. Lupus. 2011 Feb;20(2):191-205. doi:10.1177/0961203310397082.; Bradacova P, Slavik L, Ulehlova J, et al. Current Promising Biomarkers and Methods in the Diagnostics of Antiphospholipid Syndrome: A Review. Biomedicines. 2021 Feb 8; 9(2):166. doi:10.3390/biomedicines9020166.; Bertolaccini ML, Atsumi T, Koike T, et al. Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Haemost. 2005 Feb;93(2):289-97. doi:10.1160/TH04-06-0382.; Atsumi T, Ieko M, Bertolaccini ML, et al. Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum. 2000 Sep;43(9):1982-93. doi:10.1002/1529-0131(200009)43:93.0.CO;2-2.; Galli M, Beretta G, Daldossi M, et al. Different anticoagulant and immunological properties of anti-prothrombin antibodies in patients with antiphospholipid antibodies. Thromb Haemost. 1997 Mar;77(3):486-91.; Chinnaraj M, Planer W, Pengo V, Pozzi N. Discovery and characterization of 2 novel subpopulations of aPS/PT antibodies in patients at high risk of thrombosis. Blood Adv. 2019 Jun 11;3(11):1738-49. doi:10.1182/bloodadvances.2019030932.; Oosting JD, Derksen RH, Bobbink IW, et al. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: an explanation for their pathogenic mechanism? Blood. 1993 May 15;81(10):2618-25.; Matsuda J, Saitoh N, Gohchi K, et al. Anti-annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody. Am J Hematol. 1994 Sep;47(1):5 6-8. doi:10.1002/ajh.2830470112.; Sugi T, McIntyre JA. Autoantibodies to phosphatidylethanolamine (PE) recognize a kininogen-PE complex. Blood. 1995 Oct 15; 86(8):3083-9.; Vaarala O, Alfthan G, Jauhiainen M, et al. Crossreaction between antibodies to oxidised low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet. 1993 Apr 10;341(8850):923-5. doi:10.1016/0140-6736(93)91213-6.; Cugno M, Dominguez M, Cabibbe M, et al. Antibodies to tissue-type plasminogen activator in plasma from patients with primary antiphospholipid syndrome. Br J Haematol. 2000 Mar;108(4):871-5. doi:10.1046/j.1365-2141.2000.01948.x.; Острякова ЕВ, Решетняк ТМ, Айсина РБ, и др. Уровни плазминогена и ингибитора активатора плазминогена 1-го типа при антифосфолипидном синдроме. Терапевтический архив. 2012;84(5):50-7.; Jones DW, Gallimore MJ, MacKie IJ, et al. Reduced factor XII levels in patients with the antiphospholipid syndrome are associated with antibodies to factor XII. Br J Haematol. 2000 Sep;110(3):721-6. doi:10.1046/j.1365-2141.2000.02251.x.; Rampazzo P, Biasiolo A, Garin J, et al. Some patients with antiphospholipid syndrome express hitherto undescribed antibodies to cardiolipin-binding proteins. Thromb Haemost. 2001 Jan;85(1):57-62.; Bidot CJ, Jy W, Horstman LL, et al. Factor VII/VIIa: a new antigen in the anti-phospholipid antibody syndrome. Br J Haematol. 2003 Feb;120(4):618-26. doi:10.1046/j.1365-2141.2003.04161.x.; Arnout J. Antiphospholipid syndrome: diagnostic aspects of lupus anticoagulants. Thromb Haemost. 2001 Jul;86(1):83-91.; Chinnaraj M, Pengo V, Pozzi N. A Novel ELISA Assay for the Detection of Anti-Prothrombin Antibodies in Antiphospholipid Syndrome Patients at High Risk of Thrombosis. Front Immunol. 2021 Sep 8;12:741589. doi:10.3389/fimmu.2021.741589.; Решетняк ВИ, Журавель СВ, Кузнецова НК и др. Система гемостаза в норме и при трансплантации печени (обзор). Общая реаниматология. 2018;14(5):58-84.; Loeliger EA. Prothrombin as cofactor for circulating anticoagulant in systemic lupus erythematosus? Thromb Diath Haemorrh. 1959;(3):237–56.; Bajaj SP, Rapaport SI, Fierer DS, et al. A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood. 1983 Apr; 61(4):684-92.; Fujiwara K, Shimizu J, Tsukahara H, Shimada A. Lupus anticoagulant-hypoprothrombinemia syndrome and immunoglobulinA vasculitis: a report of Japanese sibling cases and review of the literature. Rheumatol Int. 2019 Oct;39(10):1811-9. doi:10.1007/s00296-019-04404-7.; Pengo V, Denas G, Bison E, et al; Italian Federation of Thrombosis Centers (FCSA). Prevalence and significance of anti-prothrombin (aPT) antibodies in patients with Lupus Anticoagulant (LA). Thromb Res. 2010 Aug; 126(2):150-3. doi:10.1016/j.thromres.2010.05.018.; Pengo V, Biasiolo A, Brocco T, et al. Autoantibodies to phospholipid-binding plasma proteins in patients with thrombosis and phospholipid-reactive antibodies. Thromb Haemost. 1996 May;75(5):721-4.; McDonnell T, Wincup C, Buchholz I, et al. The role of beta-2-glycoprotein I in health and disease associating structure with function: More than just APS. Blood Rev. 2020 Jan;39:100610. doi:10.1016/j.blre.2019.100610.; Galli M, Luciani D, Bertolini G, Barbui T. Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome. Blood. 2003 Oct 15;102(8):2717-23. doi:10.1182/blood-2002-11-3334.; Sciascia S, Sanna G, Murru V, et al. Antiprothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost. 2014 Feb;111(2):354-64. doi:10.1160/TH13-06-0509.; Permpikul P, Rao LV, Rapaport SI. Functional and binding studies of the roles of prothrombin and beta 2-glycoprotein I in the expression of lupus anticoagulant activity. Blood. 1994 May 15;83(10):2878-92.; Fleck RA, Rapaport SI, Rao LV. Anti-prothrombin antibodies and the lupus anticoagulant. Blood. 1988 Aug;72(2):512-9.; Forastiero R, Martinuzzo M, Pombo G, et al. A prospective study of antibodies to beta2-glycoprotein I and prothrombin, and risk of thrombosis. J Thromb Haemost. 2005 Jun;3(6):1231-8. doi:10.1111/j.1538-7836.2005.01295.x.; Bardin N, Alessi MC, Dignat-George F, et al. Does the anti-prothrombin antibodies measurement provide additional information in patients with thrombosis? Immunobiology. 2007;212(7):557-65. doi:10.1016/j.imbio.2007.02.001.; Pregnolato F, Chighizola CB, Encabo S, et al. Anti-phosphatidylserine/prothrombin antibodies: an additional diagnostic marker for APS? Immunol Res. 2013 Jul;56(2-3):432-8. doi:10.1007/s12026-013-8421-z.; Zigon P, Cucnik S, Ambroћi A, et al. Antibodies to phosphatidylserine/prothrombin complex as an additional diagnostic marker of APS? Lupus. 2012 Jun;21(7):790-2. doi:10.1177/0961203312444173.; Kondratieva L, Reshetnyak T, Alexandrova E, Novikov A, Lipatova N, Dobrovolskiy A, Nasonov E. The level of protrombin and antiprotrombin antibodies in patients with the antiphospholipid syndrome. Annals of the Rheumatic Diseases. 2006;65:67.; Bizzaro N, Ghirardello A, Zampieri S, et al Anti-prothrombin antibodies predict thrombosis in patients with systemic lupus erythematosus: a 15-year longitudinal study. J Thromb Haemost. 2007 Jun;5(6):1158-64. doi:10.1111/j.1538-7836.2007.02532.x.; Pengo V, Biasiolo A, Pegoraro C, et al. Antibody profiles for the diagnosis of antiphospholipid syndrome. Thromb Haemost. 2005 Jun;93(6):1147-52. doi:10.1160/TH04-12-0839.; Zigon P, Cucnik S, Ambroћi A, et al. Detection of antiphosphatidylserine/prothrombin antibodies and their potential diagnostic value. Clin Dev Immunol. 2013;2013:724592. doi:10.1155/2013/724592.; Tselios K, Sarantopoulos A, Gkougkourellas I, Boura P. The role of anti-phosphatidylserine/prothrombin antibodies in thrombotic manifestations of systemic lupus erythematosus patients. Front Neurol. 2013 Jun 4;4:66. doi:10.3389/fneur.2013.00066.; Mullen MT, Messe SR, Kasner SE, et al. Anti-Phosphatidylserine-Prothrombin Antibodies are Associated with Outcome in a TIA Cohort. Front Neurol. 2012 Sep 28;3:137. doi:10.3389/fneur.2012.00137.; Sanfelippo MJ, Joshi A, Schwartz S, et al. Antibodies to phosphatidylserine/prothrombin complex in suspected antiphospholipid syndrome in the absence of antibodies to cardiolipin or Beta-2-glycoprotein I. Lupus. 2013 Nov;22(13):1349-52. doi:10.1177/0961203313497120.; Sciascia S, Murru V, Sanna G, et al. Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities. J Thromb Haemost. 2012 Dec;10(12):2512-8. doi:10.1111/jth.12014.; Tzoulaki I, Liberopoulos G, Ioannidis JP. Assessment of claims of improved prediction beyond the Framingham risk score. JAMA. 2009 Dec 2;302(21):2345-52. doi:10.1001/jama.2009.1757.; Sciascia S, Cosseddu D, Montaruli B, et al. Risk Scale for the diagnosis of antiphospholipid syndrome. Ann Rheum Dis. 2011 Aug;70(8):1517-8. doi:10.1136/ard.2010.145177.; Otomo K, Atsumi T, Amengual O, et al. Efficacy of the antiphospholipid score for the diagnosis of antiphospholipid syndrome and its predictive value for thrombotic events. Arthritis Rheum. 2012 Feb;64(2):504-12. doi:10.1002/art.33340.; Sciascia S, Sanna G, Murru V, et al. GAPSS: the Global Anti-Phospholipid Syndrome Score. Rheumatology (Oxford). 2013 Aug; 52(8):1397-403. doi:10.1093/rheumatology/kes388.; Sciascia S, Bertolaccini ML, Roccatello D, Khamashta MA. Independent validation of the antiphospholipid score for the diagnosis of antiphospholipid syndrome. Ann Rheum Dis. 2013 Jan;72(1):142-3. doi:10.1136/annrheumdis-2012-201985.